Compare IVA & FDUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IVA | FDUS |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | France | United States |
| Employees | 77 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.8M | 719.6M |
| IPO Year | N/A | 2011 |
| Metric | IVA | FDUS |
|---|---|---|
| Price | $3.43 | $18.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | $16.20 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 1.1M | 285.3K |
| Earning Date | 03-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 11.49% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.65 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.39 |
| Revenue Next Year | $751.20 | $8.79 |
| P/E Ratio | ★ N/A | $28.29 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $16.87 |
| 52 Week High | $7.98 | $22.09 |
| Indicator | IVA | FDUS |
|---|---|---|
| Relative Strength Index (RSI) | 30.98 | 51.71 |
| Support Level | N/A | $18.16 |
| Resistance Level | $4.67 | $18.66 |
| Average True Range (ATR) | 0.18 | 0.35 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 10.27 | 61.30 |
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investment is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.